CC-chemokines are important mediators in the pathogenesis of atherosclerosis. Atherosclerosis progression is reduced by high-level, short-term inhibition of CC-chemokine activity, for example by adenoviral gene transfer. However, atherosclerosis is a chronic condition where short-term effects, while demonstrating proof-of-principle, are unlikely to provide maximum therapeutic benefit. Accordingly, we generated a recombinant lentivirus, lenti35K, encoding the broad-spectrum CC chemokine inhibitor, 35K, derived from the vaccinia virus. To investigate the effects of prolonged broad-spectrum chemokine inhibition on atherosclerosis, lenti35K, or lentiGFP or PBS were delivered to 6-week-old ApoE knockout (ApoE-KO) mice by hydrodynamic injection. Sustained lentiviral transduction and transgene expression were demonstrated by 35K mRNA and viral DNA in liver tissue, and recombinant 35K protein circulating in the plasma, 3 months after gene transfer. Plasma from lenti35K animals had reduced chemokine activity compared with plasma from lentiGFP or PBS-treated animals. Histologic analysis of aortic sinus sections revealed that atherosclerotic plaque area in lenti35K mice was significantly reduced compared with both lentiGFP and PBS controls. Furthermore, plaque macrophage content was substantially reduced in lenti35K mice. Lentiviral 35K gene transfer is a promising experimental strategy to reduce atherosclerosis progression, and demonstrates the potential of long-term CC-chemokine inhibition as a potential therapeutic target in atherosclerosis.
Atherosclerosis, the underlying cause of heart attack and stroke, is a chronic inflammatory disease characterized by the accumulation of macrophages in atherosclerotic plaque. Atherosclerotic plaque progression leads to both chronic ischemia, related to plaque growth and to acute vascular events, related to plaque rupture and thrombosis.1 Chemokines (CKs; chemotactic cytokines), particularly the CC-CK class, have important functions in the pathogenesis of atherosclerosis, including regulation of monocyte recruitment and plaque growth, plaque composition and stability.2 CC-CKs including MCP-1, RANTES and MIP-1α are present in human atherosclerotic lesions.3, 4, 5, 6 In the atherosclerosis-prone apolipoprotein E knockout (ApoE-KO) mice, targeted deletion of single CC-CKs or CK receptors significantly reduces atherosclerotic plaque progression7, 8, 9 demonstrating that a number of different CC-CK/CC-CK receptor interactions are important in atherosclerosis. Indeed, the marked functional redundancy in the CK/CK receptor signalling system suggests that a more broad-spectrum approach to CC-CK signaling may provide a more efficient strategy to reduce atherosclerosis.
The vaccinia virus (strain Lister) expresses a 35KDa protein ‘35K’ that binds to and inactivates nearly all of the CC-CK class.10, 11 Studies using an adenovirus vector engineered to express soluble 35K (Ad35K) have demonstrated that short-term expression of 35K in vivo significantly reduces atherosclerotic plaque in ApoE-KO mice.12, 13 These studies, using adenoviral gene transfer, provide important proof-of-principle that short-term, broad-spectrum CC-CK blockade can reduce atherosclerotic plaque in the early stages of atherosclerosis. However, modifying the long-term pathogenesis of atherosclerosis would likely require long-term CC-CK inhibition. Moreover, the effects of sustained broad-spectrum CC-CK inhibition in atherosclerosis might be unpredictable. Specifically, the effects of CC-CK inhibition on signalling through MCP-1/CCR2 and RANTES/CCR5 might be expected to inhibit plaque progression, whereas inhibition of CCL19/CCL21 might have the opposite effect, through blockade of macrophage emigration.14 Thus, the net effect of long-term, broad-spectrum CC-CK blockade in atherosclerosis remains an important question to be addressed.
Modified lentivirus vectors can direct stable gene transfer by evasion of host immunosurveillance15, 16, 17 through incorporation into the host genome and absence of viral gene expression.18 However, efficient transduction rates in vivo are difficult to achieve, typically requiring delivery through the portal vein,19 injection into the facial vein of neonates16 or transplantation of transduced bone marrow.17 More efficient in vivo transduction by lentiviral vectors is required to provide prolonged gene transfer with biologically important effects.20
In this study, we use hydrodynamic intravenous delivery of lentivirus to achieve prolonged and efficient expression of the chemokine-binding protein 35K, to test the effects of broad-spectrum CC-CK inhibition on atherosclerosis in ApoE-KO mice.
Efficient and persistent transduction by lenti35K and lentiGFP in vitro
We first tested the efficacy of transduction and transgene expression of lentiviral gene transfer in 293 cells in vitro. Cells transduced with lenti35K expressed soluble 35K protein that was readily detectable in culture medium (Figure 1a), with expression persisting at both 4 and 8 weeks after transduction (Figure 1b). LentiGFP also transduced 293 cells efficiently in vitro. Green fluorescent cells were visualized following transduction by 1 × 103–1 × 101 TU of purified lentiGFP (Figure 1c). These cells remained green during continuous culture for 3 months.
No toxicity of lentiviral gene transfer by hydrodynamic delivery
To assess any potential toxicity on account of our novel strategy of administering lentiviral vectors by hydrodynamic delivery we assessed liver inflammation and serum liver transaminase levels. Mice received either phosphate-buffered saline (PBS) or lentiGFP by hydrodynamic delivery or adenoviral GFP (AdGFP) and were culled after 7 days along with untreated control animals.
We found no striking alterations in liver morphology or inflammatory infiltrate in H&E stained sections from PBS- or lentiGFP-treated animals, compared with untreated controls (Figure 2a). However, in AdGFP-treated animals the livers showed a prominent inflammatory infiltrate and some necrosis. To look more closely for leukocyte influx related to either necrosis or viral immune response sections were stained with anti-S100A9 to quantify neutrophil influx21 and anti-CD3 to assess T-cell influx (Figure 2a). No significant increase in liver neutrophil or T-cell content was seen following hydrodynamic PBS or lentiGFP treatment, compared with untreated control (Figure 2b). AdGFP caused a significant elevation of both cell types in the liver, indicating that this method of gene transfer of the same protein is more inflammatory than the lentiviral delivery.
To confirm a lack of liver toxicity following lentiGFP delivery serum liver transaminases, a cardinal sign of liver damage, were measured (Figure 2b). No significant elevation of either ALT or AST was found in the PBS or lentiGFP-treated animals, with AdGFP animals showing a significant elevation of both ALT and AST above levels in untreated control animals.
Persistence of viral DNA and transgene expression after lentiviral gene transfer in vivo
We next evaluated the efficacy and persistence of lentiviral gene transfer in vivo, using hydrodynamic delivery in mice. Using RT-PCR, 35K mRNA was detected 3 months following gene transfer in liver tissue samples from lenti35K-transduced animals (Figure 3a), but not from control animals, nor in samples without RT. We used quantitative Taq-Man RT-PCR to quantify the expression levels of 35K and GFP in all animals 3 months after gene transfer. Transgene mRNA was detected at levels above the assay background (water control) exclusively in lenti35K or lentiGFP-transduced animals in the respective RT-PCR assay (Figure 3b). However, the relative level of the respective transgene expression was similar in both the lenti35K and lentiGFP groups.
To determine lentiviral vector persistence, we quantified viral DNA by PCR in mouse livers. Lenti35K viral DNA was detected in lenti35K-transduced mice 3 months after gene transfer (Figure 3c) but was not detected in either PBS or lentiGFP mouse liver DNA or water control. Correspondingly, lentiGFP viral DNA was detected 3 months after gene transfer, exclusively in lentiGFP-transduced animals (Figure 3d).
Protein expression and reduction of plasma CC-chemokine activity by lentiviral 35K gene transfer in ApoE-KO mice
We next evaluated the biological effects of in vivo hydrodynamic delivery of lenti35K on CC-CK activity in ApoE-KO mice. Twelve weeks after lenti35K delivery through hydrodynamic injection, 35K protein was detected in plasma by western blotting (Figure 4a), although at levels approximately 10-fold lower than the very high levels observed in animals that had received adenoviral gene transfer of 35K, 2 weeks previously. No 35K protein was detected in the plasma of control mice injected with either PBS or lentiGFP. Conversely, in lentiGFP-injected animals, microscopy of bone marrow cells 3 months after hydrodynamic delivery revealed green fluorescent cells that were not present in mice injected with either PBS or lenti35K (Figure 4b).
To evaluate the effect of 35K expression on CC-chemokine activity, we quantified the CCR5-directed cell migration evoked by plasma from mice that had received PBS, lenti35K or lentiGFP (Figure 4c). CCR5-directed cell migration was reduced by ∼60% in mice injected with lenti35K compared with the plasma of control mice injected with either PBS or lentiGFP. In contrast to the significant reduction in plasma CC-CK activity observed in lenti35K animals, no differences were detected in plasma concentrations of MCP-1 or RANTES between PBS, lentiGFP or lenti35K treatment groups (Table 1).
Long-term CC-chemokine inhibition with 35K reduces atherosclerosis in ApoE-KO mice
To determine the effects of long-term CC-chemokine inhibition on atherosclerotic plaque progression, 6-week-old ApoE-KO mice received either PBS, lentiGFP or lenti35K by hydrodynamic delivery. There were no differences in plasma cholesterol concentrations between the PBS, lentiGFP or lenti35K groups (Table 1). After 3 months, atherosclerotic plaque area was quantified in paraffin-embedded aortic sinus sections (Figure 5). Long-term expression of 35K, significantly reduced atherosclerotic lesion size by approximately 60% compared with either PBS and lentiGFP control mice (P<0.05). Furthermore, immunostaining with macrophage-specific antibodies mac3 and anti-Galectin-322 revealed that macrophage content in aortic sinus atherosclerotic plaques was strikingly reduced, by approximately 80%, after lenti35K gene transfer (Figure 6), compared with both PBS and lentiGFP controls.
In this study, we have demonstrated prolonged expression of a soluble, broad-spectrum recombinant CC-CK inhibitor protein, 35K, delivered by a single intravenous hydrodynamic injection of recombinant lentivirus. To investigate the effects of long-term CC-CK inhibition on atherosclerosis, we used lenti35K in ApoE-KO mice, and report the following important findings. First, lentiviral gene transfer with hydrodynamic delivery resulted in prolonged expression of soluble 35K and GFP proteins in vivo in the ApoE-KO mouse for at least 3 months, confirmed by detection of both viral DNA and transgene mRNA in liver and soluble 35K protein in the plasma. 35K protein was not detected within transduced organs, on account of the efficient secretion of the 35K protein from transduced cells, as we found previously.12 Importantly, we have shown that hydrodynamic gene delivery using lentiviral vectors significantly reduces liver inflammation and necrosis compared with adenoviral delivery. Second, lentiviral 35K expression was sufficient to reduce plasma CC-CK activity for at least 3 months. Third, prolonged expression of 35K protein significantly reduced both atherosclerotic plaque size and macrophage content in ApoE-KO mice. These results demonstrate that hydrodynamic lentiviral delivery of a soluble CC-CK inhibitor can achieve long-term inhibition of CC-CK activity sufficient to reduce atherosclerotic plaque formation. Furthermore, these studies suggest that the net effect of prolonged, broad-spectrum CC-CK inhibition is to inhibit macrophage recruitment and reduce atherosclerotic plaque progression.
Recombinant lentiviruses have emerged as useful tools to provide stable gene transfer and prolonged transgene expression,18, 20 although the use of lentiviral vectors to target inflammatory pathways in atherosclerosis has not been evaluated previously. In this study, we now demonstrate that lentiviral gene delivery of 35K can provide long-term CC-CK inhibition, leading to a significant reduction in aortic sinus atherosclerotic plaque size and plaque macrophage content. These results are a significant extension of earlier studies in which we used adenoviral-mediated gene transfer to express very high levels of 35K to achieve a short-term CC-CK inhibition and a reduction in atherosclerotic plaque.13, 23 The most striking differences between lentiviral and adenoviral 35K gene delivery are the level of protein expression achieved and the magnitude of vector-associated inflammation. Adenoviruses are able to transduce hepatocytes in vivo with a much higher efficiency than lentiviruses and therefore protein expression is significantly higher.24 Indeed, plasma from mice that had received adenovirus 35K gene transfer contained more than 10-fold higher levels of 35K protein than lenti35K plasma. Nevertheless, the lower level of 35K protein expression achieved with lenti35K, sustained over 3 months, was sufficient to reduce plasma CC-CK activity, reduce the progression of atherosclerosis and reduce macrophage recruitment into developing atherosclerotic plaques. These observations suggest that relatively low levels of 35K protein, when sustained over more prolonged periods, can exert striking biological effects. These effects of 35K gene delivery were achieved without the significant liver inflammation and necrosis that is typical of adenoviral gene delivery, characterized by leukocyte influx, and elevated serum ALT and AST levels.
We used hydrodynamic delivery to maximize the efficiency of lentiviral gene transfer in ApoE-KO mice. Hydrodynamic injection involves the rapid administration of a large volume of fluid, causing increased pressure in the liver that leads to the formation of pores on the membranes of the hepatocytes, facilitating vector entry.25, 26, 27 Previous studies have found that hydrodynamic injection is well tolerated in mice under general anesthesia and can result in hepatocyte transduction even by large DNA plasmids that would not normally be able to transduce cells in vivo.28, 29, 30 In preliminary experiments, we found that delivery of lentivirus through hydrodynamic injection significantly increased transduction efficiency compared with standard intravenous delivery and allowed a substantial reduction in virus particles to achieve comparable levels of gene transfer efficacy. Indeed, other studies have required up to 10-fold more lentivirus particles to achieve sufficient biologically significant transduction.31, 32, 33 Thus, our study shows that hydrodynamic delivery is a useful technique to improve efficacy and reduce viral dose in lentiviral gene transfer. Along with the increase viral transduction following hydrodynamic delivery, the tropism of lentiviral vectors for the liver in vivo drives efficient production and release of the soluble 35K molecule in this anatomical site.
35K blocks CC-CK activity by binding to key residues responsible for receptor activation and GAG binding.34 As such the CC-CKs are sequestered away from their receptors both being unable to actively bind to their receptor and also unable to immobilize on vascular surfaces to form a directional gradient. This will in turn prevent cells that would otherwise follow the CC-CK gradient into the atherosclerotic plaque from being able to do so. As a confirmation of this mechanism of action we observed that lenti35K significantly reduced CC-CK activity in the plasma, as judged by chemotaxis of CCR-5-transfected cells, but did not change the plasma concentration of the CC-CKs MCP-1 or RANTES, as measured by enzyme-linked immunosorbent assay (ELISA) (Table 1). This indicates that as expected 35K-bound chemokines are unable to provide a directional stimulus in a chemotaxis assay. This finding is also consistent with previous observations and suggests that CC-CKs bound to 35K protein remain detectable by ELISA, but are functionally inactive.12
The results of our study provide important new insights into the role of chemokines in atherosclerosis. 35K inhibits a broad range of CC-CKs. Some CC-CKs contribute to macrophage recruitment in atherosclerosis (for example, MCP-1/CCL2, RANTES/CCL5), whereas others regulate macrophage emigration from plaques during plaque regression (for example, CCL19 and CCL21).14 The reduction of plaque progression by prolonged broad-spectrum CC-CK blockade suggests that the dominant or net effect of CC-CKs in atherosclerosis is towards plaque progression.
In conclusion, we demonstrate efficient lentiviral gene transfer of a recombinant CC-CK binding protein, 35K, through hydrodynamic injection in vivo in ApoE-KO mice. Lenti35K delivery provided prolonged 35K expression and inhibition of chemokine activity, showing that hydrodynamic delivery is a promising strategy to improve the efficiency of lentiviral gene transfer. Prolonged 35K expression reduced both atherosclerotic plaque size and macrophage content, suggesting that long-term, broad-spectrum CC-CK inhibition is a rational therapeutic strategy to inhibit atherosclerotic plaque development.
Materials and methods
Generation of recombinant lentivirus expressing 35K
A lentiviral transfer plasmid was constructed by cloning a fragment containing the 750 bp fragment of 35K of the Vaccinia virus (Lister strain), incorporating a carboxy-terminal HA epitope tag,12 into pLenti6/V5-D-TOPO (Invitrogen, Pailey, UK). A recombinant lentivirus, lenti35K, was generated by co-transfecting the 293T17 cells with gag-pol, rev and VSV-G envelope (PMD2G) plasmids using an established protocol.35 A control recombinant lentivirus, lentiGFP, encoding enhanced green fluorescence protein (Clontech, Mountain View, CA, USA) was prepared in parallel. Virus supernatants were harvested, filtered (0.45 μm pore size, low protein affinity) and concentrated by ultracentrifugation. Titer estimates were determined by p24 ELISA as ∼1 × 109 transducing units (TU)/ml.
Transduction of Lenti35k and LentiGFP in vitro
Purified lentiviruses were added to 293 cells at a range of titers (1 × 105–1 × 101) then incubated in the presence of polybrene (Sigma-Aldrich, Dorset, UK) (8 μg ml−1) for 24 h before changing to fresh media. Transduced cells were left to incubate for periods of up to 3 months. Media was collected and frozen periodically for subsequent detection of soluble 35K protein using western blotting. Fluorescent cells transduced with LentiGFP were visualized under an inverted microscope and digital images were recorded (Nikon TE2000U).
Animals and gene transfer
ApoE-KO mice on a C57BL6 background (Jax Laboratories, ME, USA) were fed a regular chow diet for the duration of the experiment (n=7–9/treatment group). At 6 weeks of age mice received either PBS or lentivirus by tail vein hydrodynamic injection (7.5 × 107 TU diluted in 10% w/v body weight PBS, typically 2–2.5 ml), under isofluorane anesthesia.28
Twelve weeks following lentiviral delivery, mice were killed using an overdose of isofluorane anesthesia and plasma was collected by cardiac puncture. Mice were perfuzed with PBS through the left ventricle. Pieces of liver were collected and snap frozen for real-time PCR experiments. The femur, fibula and tibia were removed for collection of bone marrow. The heart and aorta were then perfusion-fixed using 4% paraformaldehyde in PBS (5 ml). Hearts, with aortic roots, were excised and fixed overnight in paraformaldehyde then embedded in paraffin. All animal procedures were carried out in accordance with the UK Home Office Animals (Scientific Procedures) Act 1986, and after local ethical review.
For toxicity experiments PBS or lentiGFP (7.5 × 107 TU diluted in 10% w/v body weight PBS, typically 2–2.5 ml) were administered by hydrodynamic delivery as above, or AdGFP (1 × 1011 TU in 0.3 ml) by conventional i.v. injection. Mice were killed 1 week post gene transfer, with serum and liver samples being prepared as above.
Paraffin-embedded liver samples were sectioned (7 μm) and stained with hematoxylin and eosin (Sigma), anti S100A9 antibody (a generous gift of Nancy Hogg, Cancer Research UK, London, UK) at 1 μg ml−1 or anti-CD3 antibody (DAKO) at 1:200. This was followed by a secondary biotinylated antibody (Vector Laboratories, UK) then avidin–biotin–AP complex and visualized with Vector Red alkaline phosphatase substrate (Vector Laboratories, UK).
Serum transaminase measurements
Liver enzymes were measured in serum samples using commercial enzymatic assays (Infinity ALT and AST liquid stable reagent, Thermo Scientific, Waltham, MA, USA) according to the manufacturer's instructions.
Real-time RT-PCR for detection of lentivirus transgene expression
Frozen liver samples (5 mg) were homogenized in Trizol. RNA was extracted and further purified using the RNeasy protocol (Qiagen, West Sussex, UK). RNA was reverse transcribed using Superscript II according to the manufacturer's instructions (Invitrogen). Taq-man custom gene expression assays (FAM-labeled) were designed to quantify 35K and GFP cDNA (35K—forward: IndexTermGCTGATGGAAACACAGTGAATGC, reverse: IndexTermCGGGAGAGTCCTTACCTTGTC, probe: IndexTermACGCTGGACAATCTA, GFP—forward: IndexTermGAGCGCACCATCTTCTTCAAG, reverse: IndexTermTGTCGCCCTCGAACTTCAC, probe: IndexTermACGACGGCAACTACA). All real-time PCRs were performed using 100 ng RNA equivalent. Gene expression data were normalized to α-actin (housekeeping gene) and normalized to the highest expressing animal for each assay (GFP and 35K) using the ΔCt method. Reaction products from the 35K assay were run on a 3% agarose gel and visualized using ethidium bromide.
Real-time PCR for detection of viral DNA
Frozen livers (0.3 g) were homogenized in extraction buffer (10 mM Tris-HCl pH 8.5 0.45% Non-idet P40, 0.45% Tween-20, 0.5 mg ml−1 Proteinase K) and DNA was extracted using phenol/chloroform and re-suspended in TE buffer. All real-time PCRs were performed on 500 ng of genomic DNA using SyberGreen I (BioRad, Hertfordshire, UK) in a 10 μl reaction with 1 μM of primers. Gene expression data was normalized to GAPDH (housekeeping gene) and expressed as relative to high expressing animal for each assay (GFP and 35K) using the ΔCt method. Reaction products from the 35K assay were run on a 3% agarose gel and visualized using ethidium bromide.
Harvesting of bone marrow
The femur, fibula and tibia were cleaned of all muscle tissue. The bone marrow was then flushed out using sterile PBS (10 ml) with a needle (26 G) and syringe (10 ml). Cells were then re-suspended with a 19-G needle and passed through a cell strainer before plating out on 9 cm plates in RPMI-containing L-cell-conditioned media. Cells were left for 72 h before viewing and capturing digital images (Zeiss) under an inverted fluorescent microscope.
To detect recombinant 35K protein in cell media, 10–20 μl was separated on 14% SDS-PAGE gels. Following transfer to PVDF membranes, 35K protein was detected using rabbit polyclonal anti-35K antibody diluted to 1:2000 (a generous gift from Peter Turner, University of Florida, Gainesville, FL, USA) followed by an anti-rabbit secondary antibody conjugated to horseradish peroxidase diluted 1:1500.
To evaluate 35K in mouse plasma, 200 μl of plasma was incubated overnight (4 °C) with monoclonal anti-HA agarose-conjugated beads (Sigma). Beads were washed, diluted 1:1 in 2 × SDS sample buffer and proteins were denatured by heating at 95 °C for 3 min. Beads were pelleted by centrifugation and the supernatant separated on 14% SDS-PAGE gels, transferred and immunoblotted as described above.
Quantification of chemokine activity
Specific CCR5 receptor-directed cell migration was assessed using transwell membranes (6.0 mm diameter, 8 μm pore size, Receptor Technologies, Banbury, UK) as described earlier.12 Briefly, 293 cells were grown to 50% confluence in Dulbecco's modified Eagle's media (DMEM)+10% (v/v) fetal calf serum, then co-transfected (Fugene6, Roche, Hertfordshire, UK) with plasmids encoding CCR5 and EGFP to facilitate visualization. Transfected cells were harvested and allowed to migrate overnight towards mouse plasma (10 μl) placed in the lower chamber. Migrated cells on the underside of membranes were fixed and quantified by computer analysis of EGFP fluorescence in confocal microscope images. Each experimental sample was analyzed in duplicate, and three separate images were quantified for each membrane.
Histology and immunohistochemistry of atherosclerosis in aortic root sections
Serial transverse sections (7 μm) of the paraffin-embedded hearts were taken through the aortic root. Serial sections were collected from the whole of the aortic root for which all three valve cusps were visible. To quantify lesion area, 3 sections were chosen from base, middle and top of the aortic root, being 80 μm apart across a standardized 160 μm area. They were stained with Masson-Goldner/elastin stain (VWR international, Leicestershire, UK) for evaluation of atherosclerotic plaque size (mm2). For evaluation of macrophage plaque content, paraffin sections were stained with mouse macrophage antigen Mac-3 (Pharmingen, Oxford, UK, rat anti-mouse)at a 1:50 dilution overnight (4 °C) or anti-Galectin 3 (R&D Systems, Abingdon, UK) at 1:200 for 2 h at room temperature. This was followed by a secondary anti-rat or anti-goat biotinylated antibody, respectively (Vector Laboratories, Peterborough, UK) then avidin–biotin–AP complex and visualized with Vector Red alkaline phosphatase substrate (Vector Laboratories). Sections (n=3/mouse) were quantified from digitized microscopic images using Image Pro-Plus software (Media Cybernetics, Bethesda, MD, USA).
Detection of plasma chemokines in mouse plasma
Mouse RANTES and MCP-1 CC-CKs were detected in mouse plasma (50 μl) using ELISA kits (Quantikine, R&D systems) following the manufacturer's instructions.
Plasma lipids were measured using an enzymatic assay (Roche) on heparinized blood plasma using a Cobas Mira Plus automated analyzer (Roche).
All values are expressed as the mean±s.e.m. Data were analyzed using a one-way analysis of variance and the Tukeys post hoc test of significance, comparing the controls to the treatment groups. A value of P<0.05 was the criterion of significance.
Bursill CA, Channon KM, Greaves DR . The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics. Curr Opin Lipidol 2004; 15: 145–149.
Glass CK, Witztum JL . Atherosclerosis. the road ahead. Cell 2001; 104: 503–516.
Wilcox JN, Nelken NA, Coughlin SR, Gordon D, Schall TJ . Local expression of inflammatory cytokines in human atherosclerotic plaques. J Atheroscler Thromb 1994; 1: S10–S13.
Haley KJ, Lilly CM, Yang JH, Feng Y, Kennedy SP, Turi TG et al. Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation 2000; 102: 2185–2189.
Reape TJ, Rayner K, Manning CD, Gee AN, Barnette MS, Burnand KG et al. Expression and cellular localization of the CC chemokines PARC and ELC in human atherosclerotic plaques. Am J Pathol 1999; 154: 365–374.
Greaves DR, Hakkinen T, Lucas AD, Liddiard K, Jones E, Quinn CM et al. Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2001; 21: 923–929.
Boring L, Gosling J, Cleary M, Charo IF . Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394: 894–897.
Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 1999; 103: 773–778.
Braunersreuther V, Zernecke A, Arnaud C, Liehn EA, Steffens S, Shagdarsuren E et al. Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2007; 27: 373–379.
Burns JM, Dairaghi DJ, Deitz M, Tsang M, Schall TJ . Comprehensive mapping of poxvirus vCCI chemokine-binding protein. Expanded range of ligand interactions and unusual dissociation kinetics. J Biol Chem 2002; 277: 2785–2789.
Smith CA, Smith TD, Smolak PJ, Friend D, Hagen H, Gerhart M et al. Poxvirus genomes encode a secreted, soluble protein that preferentially inhibits beta chemokine activity yet lacks sequence homology to known chemokine receptors. Virology 1997; 236: 316–327.
Bursill C, Cai S, Channon KM, Greaves DR . Adenoviral-mediated delivery of a viral chemokine binding protein blocks CC-chemokine activity in vitro and in vivo. Immunobiology 2003; 207: 1–10.
Bursill CA, Choudhury RP, Ali Z, Greaves DR, Channon KM . Broad-spectrum CC-chemokine blockade by gene transfer inhibits macrophage recruitment and atherosclerotic plaque formation in apolipoprotein E-knockout mice. Circulation 2004; 110: 2460–2466.
Trogan E, Feig JE, Dogan S, Rothblat GH, Angeli V, Tacke F et al. Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci USA 2006; 103: 3781–3786.
Kobayashi H, Carbonaro D, Pepper K, Petersen D, Ge S, Jackson H et al. Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector. Mol Ther 2005; 11: 776–789.
Carbonaro DA, Jin X, Petersen D, Wang X, Dorey F, Kil KS et al. In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knockout mice: a novel form of enzyme replacement therapy for ADA deficiency. Mol Ther 2006; 13: 1110–1120.
Bot I, Guo J, Van Eck M, Van Santbrink PJ, Groot PH, Hildebrand RB et al. Lentiviral shRNA silencing of murine bone marrow cell CCR2 leads to persistent knockdown of CCR2 function in vivo. Blood 2005; 106: 1147–1153.
Kohn D . Lentiviral vectors ready for prime-time. Nat Biotechnol 2007; 25: 65–66.
Ren B, O’Brien BA, Swan MA, Koina ME, Nassif N, Wei MQ et al. Long-term correction of diabetes in rats after lentiviral hepatic insulin gene therapy. Diabetologia 2007; 50: 1910–1920.
Amado RG, Chen ISY . Lentiviral vectors—the promise of gene therapy within reach? Science 1999; 285: 674–676.
Hobbs JA, May R, Tanousis K, McNeill E, Mathies M, Gebhardt C et al. Myeloid cell function in MRP-14 (S100A9) null mice. Mol Cell Biol 2003; 23: 2564–2576.
Papaspyridonos M, McNeill E, de Bono JP, Smith A, Burnand KG, Channon KM et al. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol 2008; 28: 433–440.
Ali ZA, Bursill CA, Hu Y, Choudhury RP, Xu Q, Greaves DR et al. Gene transfer of a broad spectrum CC-chemokine inhibitor reduces vein graft atherosclerosis in apolipoprotein E-knockout mice. Circulation 2005; 112: I235–I241.
St George JA . Gene therapy progress and prospects: adenoviral vectors. Gene Therapy 2003; 10: 1135–1141.
Crespo A, Peydro A, Dasi F, Benet M, Calvete JJ, Revert F et al. Hydrodynamic liver gene transfer mechanism involves transient sinusoidal blood stasis and massive hepatocyte endocytic vesicles. Gene Therapy 2005; 12: 927–935.
Kobayashi N, Nishikawa M, Hirata K, Takakura Y . Hydrodynamics-based procedure involves transient hyperpermeability in the hepatic cellular membrane: implication of a nonspecific process in efficient intracellular gene delivery. J Gene Med 2004; 6: 584–592.
Zhang G, Gao X, Song YK, Vollmer R, Stolz DB, Gasiorowski JZ et al. Hydroporation as the mechanism of hydrodynamic delivery. Gene Therapy 2004; 11: 675–682.
Hibbitt OC, Harbottle RP, Waddington SN, Bursill CA, Coutelle C, Channon KM et al. Delivery and long-term expression of a 135Kb LDLR genomic DNA locus in vivo by hydrodynamic tail vein injection. J Gene Med 2007; 9: 488–497.
Zhang G, Song YK, Liu D . Long-term expression of human alpha1-antitrypsin gene in mouse liver achieved by intravenous administration of plasmid DNA using a hydrodynamics-based procedure. Gene Therapy 2000; 7: 1344–1349.
Liu F, Song Y, Liu D . Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Therapy 1999; 6: 1258–1266.
De Palma M, Venneri MA, Naldini L . In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum Gene Ther 2003; 14: 1193–1206.
Lamikanra A, Myers KA, Ferris N, Mitrophanous KA, Carroll MW . In vivo evaluation of an EIAV vector for the systemic genetic delivery of therapeutic antibodies. Gene Therapy 2005; 12: 988–998.
Bao L, Jaligam V, Zhang XY, Kutner RH, Kantrow SP, Reiser J . Stable transgene expression in tumors and metastases after transduction with lentiviral vectors based on human immunodeficiency virus type 1. Hum Gene Ther 2004; 15: 445–456.
Zhang L, Derider M, McCornack MA, Jao SC, Isern N, Ness T et al. Solution structure of the complex between poxvirus-encoded CC chemokine inhibitor vCCI and human MIP-1beta. Proc Natl Acad Sci USA 2006; 103: 13985–13990.
Klages N, Zufferey R, Trono D . A stable system for the high-titer production of multiply attenuated lentiviral vectors. Mol Ther 2000; 2: 170–176.
We gratefully acknowledge the kind donation of rabbit polyclonal 35K antibody from Peter Turner and Dick Moyer, Department of Molecular Genetics and Microbiology, University of Florida. We gratefully acknowledge the kind donation of rat monoclonal S100A9 antibody (2B10) from Nancy Hogg, Cancer Research UK, London Research Institute, UK. We thank the Lentiviral Vector Production Unit of the Swiss Institute of Technology Lausanne (EPFL), supported by the Association Française contre les Myopathies (AFM), for the production of the lentivirus used in the in vivo studies. We thank Ashley Hale for assistance with the liver transaminase assays. This work, in the laboratories of DRG and KMC, was supported by the British Heart Foundation.
About this article
Cite this article
Bursill, C., McNeill, E., Wang, L. et al. Lentiviral gene transfer to reduce atherosclerosis progression by long-term CC-chemokine inhibition. Gene Ther 16, 93–102 (2009). https://doi.org/10.1038/gt.2008.141
Lentivirus-Mediated hFGF21 Stable Expression in Liver of Diabetic Rats Model and Its Antidiabetic Effect Observation
Human Gene Therapy (2020)
Journal of Clinical Medicine (2020)
Trends in Molecular Medicine (2018)
Molecular Therapy - Nucleic Acids (2018)
PLOS ONE (2017)